Fibromyalgia Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

Fibromyalgia Market Report Insight

Fibromyalgia companies are Eli Lilly, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., Aptinyx Prismic Pharmaceuticals, Astellas Pharma Inc., and others.

LAS VEGAS, NEVADA, UNITED STATES, July 11, 2024 /EINPresswire.com/ -- DelveInsight’s “Fibromyalgia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Fibromyalgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fibromyalgia Market Forecast

Some of the key facts of the Fibromyalgia Market Report:
The Fibromyalgia market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
The Fibromyalgia market is expected to experience significant growth during the forecast period (2024–2034). The positive trend in market growth is a direct consequence of various market-driving factors such as the rising prevalence of fibromyalgia, technological advancements, increasing awareness of the disease, and the development of innovative treatment options.
The current fibromyalgia market is dominated by big pharmaceutical companies like Pfizer, Cogentrix Pharma, Eli Lilly and Company offering various approved therapies such as LYRICA, CYMBALTA, and SAVELLA for the treatment of fibromyalgia and is anticipated to experience significant growth in the coming years.
To propel the market in the coming years, several companies like Tonix Pharmaceutical and UCB Biopharma SRL developing their assets like TNX102 SL and rozanolixizumab for fibromyalgia. Due to the anticipated approval of all emerging therapies that are under development in the coming years, the overall fibromyalgia therapeutics market is expected to grow at a significant CAGR over the forecast period [2024–2034].
Key Fibromyalgia Companies: Eli Lilly and Company, Pfizer, Virios Therapeutics, Novartis AG, Allergan plc, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., Aptinyx Prismic Pharmaceuticals, Astellas Pharma Inc., and others
Key Fibromyalgia Therapies: LYRICA (pregabalin), CYMBALTA (durotexine), TNX102 SL, Rozanolixizumab, and others
The Fibromyalgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fibromyalgia pipeline products will significantly revolutionize the Fibromyalgia market dynamics.

Fibromyalgia Overview
Fibromyalgia, also known as fibromyalgia syndrome, is a widespread and complex chronic pain condition characterized by musculoskeletal pain, fatigue, localized tenderness, and significant impact on emotional, physical, and social well-being. While its exact cause remains unknown, hereditary factors are believed to play a primary role. Common symptoms include chronic muscle pain, fatigue, sleep disturbances, and tender points. Patients may also experience depression, headaches, and difficulty concentrating. The etiology and pathogenesis of fibromyalgia involve dysfunction of the central and autonomic nervous systems, neurotransmitters, hormones, immune system, external stressors, and psychological factors.

Diagnosing fibromyalgia does not rely on a specific test but involves ruling out other conditions that may present similar symptoms. Healthcare providers typically perform a physical exam, discuss symptoms with the patient, and may conduct blood tests or imaging to exclude other potential causes. Diagnosis is often based on the patient's symptom history and medical evaluation.

Treatment for fibromyalgia is multifaceted and often includes a combination of medications and lifestyle changes tailored to individual needs. Healthcare providers typically adopt an empirical approach, adjusting medications and dosages until finding the most effective regimen for each patient. The US FDA has approved three medications for fibromyalgia—LYRICA (pregabalin), CYMBALTA (duloxetine), and SAVELLA (milnacipran). LYRICA is an anti-epileptic, while CYMBALTA and SAVELLA are antidepressants. In addition to these approved therapies, various medications are used to manage the spectrum of fibromyalgia symptoms. Non-pharmacological treatments such as therapy, regular aerobic exercise, stress reduction techniques, and others also form an integral part of fibromyalgia management.

Key players in the global market for fibromyalgia treatment include UCB Biopharma SRL, Tonix Pharmaceuticals, and others, focusing on developing therapies to address the unmet needs of patients with fibromyalgia.

Fibromyalgia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
As per analysis, the global mean prevalence of fibromyalgia was 2.7 % and the mean rate was 3.1 % in America, and 2.5 % in Europe.
Based on our analysis it is estimated that the prevalence of fibromyalgia in the general population was estimated in the United States to be around 2% and it affects females more frequently than males.
As per analysis, it is estimated that around 2 million people in Japan have fibromyalgia and it is common among women in their 30s and 40s.
Our analysis suggests an overall age- and sex-adjusted prevalence for fibromyalgia was around 3% (around 5% in women and 2% in men). It was also found that peak prevalence in men was found in middle age whereas in women the prevalence steadily increases with age.
Fibromyalgia Epidemiology Segmentation:
The Fibromyalgia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Fibromyalgia
Prevalent Cases of Fibromyalgia by severity
Gender-specific Prevalence of Fibromyalgia
Diagnosed Cases of Episodic and Chronic Fibromyalgia

Download the report to understand which factors are driving Fibromyalgia epidemiology trends @ Fibromyalgia Epidemiology Forecast

Fibromyalgia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fibromyalgia market or expected to get launched during the study period. The analysis covers Fibromyalgia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Fibromyalgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Fibromyalgia Marketed Drugs
LYRICA (pregabalin): Pfizer
CYMBALTA (durotexine): Eli Lilly and Company
Fibromyalgia Emerging Drugs
TNX102 SL: Tonix Pharmaceutical
Rozanolixizumab: UCB Biopharma SRL

Fibromyalgia Market Outlook
The treatment landscape for fibromyalgia is diverse, typically combining medications with lifestyle adjustments due to the nature of the disease. Physicians often employ an empirical approach, adjusting medications and doses until finding the most effective regimen for each patient. In the United States, the FDA has approved three drugs for fibromyalgia treatment: LYRICA (pregabalin), CYMBALTA (duloxetine), and SAVELLA (milnacipran).

In addition to these medications, over-the-counter pain relievers like acetaminophen and ibuprofen can alleviate symptoms. Physical therapy, occupational therapy, and counseling are also integral to managing the condition. Incorporating exercise, stress management techniques, maintaining good sleep habits, and adopting a healthy lifestyle are essential components of fibromyalgia treatment.

The fibromyalgia market is expected to experience significant changes in the coming years, driven by increased global healthcare expenditures. Leading global players such as UCB Biopharma SRL, Tonix Pharmaceuticals, and Virios Therapeutics, Inc., among others, are poised to influence these developments. Ongoing research efforts offer promise for more effective treatments and potentially a cure for this challenging condition. According to DelveInsight, the fibromyalgia market in the 7MM (Seven Major Markets) is forecasted to undergo notable transformations from 2020 to 2034.

Scope of the Fibromyalgia Market Report:

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Fibromyalgia Companies: Eli Lilly and Company, Pfizer, Virios Therapeutics, Novartis AG, Allergan plc, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., Aptinyx Prismic Pharmaceuticals, Astellas Pharma Inc., and others
Key Fibromyalgia Therapies: LYRICA (pregabalin), CYMBALTA (durotexine), TNX102 SL, Rozanolixizumab, and others
Fibromyalgia Therapeutic Assessment: Fibromyalgia current marketed and Fibromyalgia emerging therapies
Fibromyalgia Market Dynamics: Fibromyalgia market drivers and Fibromyalgia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Fibromyalgia Unmet Needs, KOL’s views, Analyst’s views, Fibromyalgia Market Access and Reimbursement

To know more about Fibromyalgia companies working in the treatment market, visit @ Fibromyalgia Clinical Trials and Therapeutic Assessment

Table of Contents
1. Fibromyalgia Market Report Introduction
2. Executive Summary for Fibromyalgia
3. SWOT analysis of Fibromyalgia
4. Fibromyalgia Patient Share (%) Overview at a Glance
5. Fibromyalgia Market Overview at a Glance
6. Fibromyalgia Disease Background and Overview
7. Fibromyalgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Fibromyalgia
9. Fibromyalgia Current Treatment and Medical Practices
10. Fibromyalgia Unmet Needs
11. Fibromyalgia Emerging Therapies
12. Fibromyalgia Market Outlook
13. Country-Wise Fibromyalgia Market Analysis (2020–2034)
14. Fibromyalgia Market Access and Reimbursement of Therapies
15. Fibromyalgia Market Drivers
16. Fibromyalgia Market Barriers
17. Fibromyalgia Appendix
18. Fibromyalgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Fibromyalgia Pipeline

"Fibromyalgia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fibromyalgia market. A detailed picture of the Fibromyalgia pipeline landscape is provided, which includes the disease overview and Fibromyalgia treatment guidelines.

Fibromyalgia Epidemiology

DelveInsight's 'Fibromyalgia Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Fibromyalgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here

Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release